SRNE - Sorrento furthers Mesenchymal Stem Cell Program to the pipeline of Covid-19 rescue therapies

Sorrento Therapeutics (SRNE) enters into an exclusive license agreement with Personalized Stem Cells to acquire global rights to its adipose derived mesenchymal stem cells (or MSCs), which have been cleared for a Phase 1 clinical trial by the FDA.These will be used for patients suffering from acute respiratory distress syndrome (or ARDS) associated with COVID-19.Sorrento will be assuming responsibility for executing the Phase 1 trial, which is targeted to enroll about 20 hospitalized COVID-19 patients in California.Stem cells have the potential to reduce the long-term effects associated with pulmonary tissue damage for these patients.Previously: Sorrento R&D event for COVID-19 on October 13 (Oct. 5)

For further details see:

Sorrento furthers Mesenchymal Stem Cell Program to the pipeline of Covid-19 rescue therapies